Dr. West on 4 Important Upcoming Clinical Trial Results

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses the anticipated results of 4 lung cancer clinical trials.

1. FORIS-M trial examining the single agent use of talactoferrin in previously treated patients with non-small cell lung cancer (NSCLC).
2. ECOG 1505 phase III trial looking at adjuvant chemotherapy with or without bevacizumab in completely resected NSCLC.
3. RADIANT trial examining adjuvant erlotinib for EGFR-positive NSCLC patients, noteworthy because of its isolation of the EGFR mutation.
4. The evaluation of the recombinant MAGE-A3 vaccine platform as adjuvant therapy in MAGE-A3-Positive NSCLC in addition to or instead of standard chemotherapy.